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isk factors for Hepatitis C virus (HCV) transmission and efﬁ-
iency of antiviral therapy in chronically infected patients
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zijan3, D. Vukovic1, N. Ruzman1, J. Barbic4
Institute of Public Health for Osijek-Baranya County, Osijek, Croatia
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Background: This study monitored the prevalence and geno-
ype distribution of HCV in patients suspected for infection as well
s risk factors for infection and transmission of HCV in northeast
roatia.
Methods: From January 2009 to December 2011, 405 plasma
pecimens of patients suspected for HCV infection were tested by
he COBAS TaqMan HCV test v2.0 (Roche Diagnostics); 77 HCV-
ositive samples were genotyped using the Linear Array HCV
enotyping test (Roche); 33 HCV-positive patients with unfavor-
ble liver tests were further treated with anti-viral therapy and
onitored at weeks 28 and 53. Risk factors for HCV infection
nd transmissionwere analyzed frompatient-ﬁlled questionnaires
age, sex, riskbehavior etc.) and their clinical data (age at initialHCV
nfection, degree of liver inﬂammation and ﬁbrosis).
Results: Out of 405 tested patients, 198 (48.8%) were HCV-
ositive and the highest prevalence of infection was found in men
ndwomenbetween30and40yearsof age.HCVgenotypedistribu-
ion in northeast Croatia was similar to other European regions: G1
as the most common (66.6%), followed by G3 (22.1%), G4 (10.4%),
nd G2 (1.3%); genotypes G5 and G6 were not detected. Viral
herapy evaluated at week 53 demonstrated that 58% of patients
ere virus-free, 12% had lower viral load while 12% showed no
hange in viral load. Moreover, HCV G1-infected patients showed
delayed response to antiviral therapy when compared to G3
nd G4-infected patients: 31% G1-, 40% G3- and 50% G4-infected
atients were virus-free at week 28; 58% G1-, 60% G3- and 50% G4-
nfected patientswere virus-free atweek 53. Signiﬁcant risk factors
orHCV infection and transmission innortheast Croatia includehis-
ory of blood transfusion, surgery before the year 1993, and body
iercing in 31-40 year-old men (p<0.05).
Conclusion:Our results strengthen the importanceof early test-
ng for HCV infection in men showing the symptoms of chronic
epatitis (muscle pain, appetite loss, history of jaundice) since they
re statistically more often intravenous drug, piercing, and tattoo
sers then women in our region.
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Variation of interleukin-28B at rs12979860 in injection drug
users with HCV infection in a Chinese population
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Background:Hepatitis C virus (HCV) infection is a leading cause
of liver disease globally. Recently, several genome-wide associa-
tion studies have reported the strong association between single
nucleotide polymorphisms (SNPs) near the interleukin-28B (IL28B)
gene and the treatment outcome for chronicHCV infection. InHong
Kong, needle-sharing in injection drug users (IDU) continues to be a
major route of HCV transmission. We conducted a follow-up study
on HCV RNA-positive IDU to determine the genotype frequency of
a SNP upstream of IL28B and their association with HCV genotype.
Methods: A total of 273 IDU positive for anti-HCV and HCV
RNAwere included. Genomic DNAwas extracted fromwhole blood
samples, and the most strongly associated SNP near the IL28 gene,
rs12979860, was determined by real-time PCR using a custom Taq-
Man genotyping kit.
Results: The rs12979860 genotype distribution was CC in 237
IDU (86.8%), CT in 35 IDU (12.8%), and one case (0.4%) with TT
genotype. The distribution of rs12979860 genotypes in the IDU
population was in Hardy-Weinberg equilibrium (P = 0.810). Varia-
tion in the IL28Bgenotypeswasnot observed as comparedwith300
healthy blood donors (CC: 87.0%, CT: 11.7%, and TT: 1.3%; P = 0.430).
With regard to HCV genotype, HCV 1b and HCV 6a were the two
commonest genotypes circulating in our local IDU population. Of
the 105 IDU infected with HCV genotype 1 and 145 IDU with geno-
type 6, the frequency of the rs12979860 CC genotype was 81.9%
and 88.3%, respectively, which were not different signiﬁcantly (P =
0.509).
Conclusion: In conclusion, the favorable rs12979860 CC geno-
type frequently observed in our Chinese population supports a
potential role of incorporating IL28B SNPgenotyping for the clinical
workup of patients infected with HCV genotypes 1 and 6. Integrat-
ing the assessment of host and viral factors (age, gender, and HCV
genotype) in combination with pre-treatment screening of IL28B
rs12979860 polymorphism may provide useful prognostic infor-
mation prior to interferon-based combination therapy for chronic
HCV infection. This combined assessment may facilitate the devel-
opment of new therapeutic approaches for the non-responders to
conventional HCV therapies.
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